Every 10-Q that Kymera Therapeutics, Inc. (KYMR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KYMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYMR filings page.
Kymera Therapeutics reported higher collaboration revenue for the quarter ended June 30, 2026, driven by milestone activity in its partnerships. Collaboration revenue reached $65.0 million versus $11.5 million a year earlier, and was $99.4 million for the first half of 2026 versus $33.6 million in 2025. Quarterly operating expenses rose to $140.6 million, mainly from increased R&D spending of $119.5 million, leading to a net loss of $61.2 million (basic and diluted loss per share $0.62), compared with a $76.6 million loss in the prior-year quarter.
Interest income from the company’s investment portfolio contributed $14.4 million in other income in the quarter. As of June 30, 2026, Kymera held $1,505 million in cash, cash equivalents and marketable securities and reported stockholders’ equity of $1,509.3 million. Net cash used in operating activities was $142.9 million for the first half of 2026. Management states this liquidity is expected to fund operations and capital expenditures for at least twelve months, while the company remains a clinical-stage biotech with ongoing losses and a need for substantial future funding.
Kymera Therapeutics reported higher collaboration revenue and a wider loss for the quarter ended March 31, 2026. Collaboration revenue rose to $34.4 million, driven by recognition of deferred revenue from its Gilead CDK2 partnership, while the company recorded a net loss of $69.2 million and basic and diluted net loss per share of $0.71.
Total operating expenses increased to $118.5 million, led by research and development spending of $98.2 million as multiple programs advance. Kymera ended the quarter with $1.55 billion in cash, cash equivalents and marketable securities and $1.54 billion of stockholders’ equity, providing substantial funding for its clinical-stage targeted protein degradation pipeline.
The company’s Sanofi IRAK4 collaboration did not contribute revenue this quarter after prior milestones, while Gilead collaboration revenue fully relieved related deferred revenue. After quarter-end, Gilead exercised its option to exclusively license KT-200, triggering a $45 million milestone expected to be recognized as second-quarter 2026 revenue.
Kymera Therapeutics (KYMR) filed its Q3 2025 10-Q, highlighting a strong liquidity position and ongoing collaboration-driven revenue. Cash, cash equivalents and marketable securities totaled $978.7 million as of September 30, 2025, supported by a June–July follow-on offering with approximately $288.4 million in aggregate gross proceeds. Total assets were $1.10 billion and stockholders’ equity was $946.3 million.
For Q3 2025, the company reported collaboration revenue of $2.764 million, research and development expense of $74.094 million, and a net loss of $82.175 million (basic and diluted net loss per share $0.94). Year-to-date through Q3, collaboration revenue was $36.341 million, net loss was $224.370 million, and cash used in operating activities was $166.144 million. Deferred revenue was $37.236 million, including $37.2 million from the $40.0 million upfront payment in the Gilead molecular glue degrader agreement, to be recognized over an estimated 1.5 years. Under the Sanofi IRAK4 collaboration, the company recognized $33.6 million year-to-date and remains eligible for up to $975 million in future milestones tied to development, regulatory and commercial events. As of October 31, 2025, common shares outstanding were 71,949,027.
Kymera Therapeutics (KYMR) reported Q2 2025 interim results showing strong liquidity while continuing to invest heavily in R&D. The company held $963.1 million of combined cash, cash equivalents and marketable securities at June 30, 2025 and completed a June follow-on that generated aggregate gross proceeds of approximately $288.4 million.
Collaboration revenue totaled $11.5 million for the quarter and $33.6 million for the six months, mainly from the Sanofi collaboration; Kymera also received a $40.0 million upfront payment under an option agreement with Gilead. R&D expense rose to $158.6 million for the six months, contributing to a six-month net loss of $142.2 million and an accumulated deficit of $896.8 million.